Roth Sees Significant Advantages to TG Therapeutics' (TGTX) TGR-1202 vs. Gilead's (GILD) Zydelig; Reiterates 'Focus Pick' Rating
Tweet Send to a Friend
Roth Capital comments on TG Therapeutics (Nasdaq: TGTX) following Gilead (Nasdaq: GILD) news out earlier that its PI3K inhibitor idealisib ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
